Literature DB >> 11443773

Catabolism in uremia: the impact of metabolic acidosis.

H A Franch1, W E Mitch.   

Abstract

Chronic metabolic acidosis stimulates the catabolism of bone and muscle in experimental animals and humans. The toxicity caused by acidosis involves changes in endocrine function and toxicity arising from the homeostatic responses that are activated by the body to maintain pH near normal levels. Glucocorticoids, insulin, insulin-like growth factor-1, and parathyroid hormone play important roles in the homeostatic responses of bone and muscle to acid. Bone buffering of acid and the resulting increase in renal calcium excretion leads to negative calcium balance. Activation of the ubiquitin-proteasome proteolytic system and branched-chain ketoacid dehydrogenase in muscle, along with hepatic glutamine synthesis in the liver and renal glutamine uptake, are homeostatic mechanisms that cause negative nitrogen balance and loss of muscle mass. Treating the acidosis of chronic renal insufficiency improves both bone and muscle metabolism by reducing the loss of calcium and protein and amino acids in the two organs, respectively. Thus, treating acidosis suppresses both bone and muscle catabolism in patients with normal and reduced renal function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11443773

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

1.  Chronic kidney disease epidemic: myth and reality.

Authors:  Filippo Mangione; Antonio Dal Canton
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Dialysis: A step towards optimal dialysate bicarbonate concentration.

Authors:  Carlo Basile; Carlo Lomonte
Journal:  Nat Rev Nephrol       Date:  2013-08-13       Impact factor: 28.314

Review 3.  Nutritional treatment in chronic kidney disease: the concept of nephroprotection.

Authors:  Eleonora Riccio; Antonella Di Nuzzi; Antonio Pisani
Journal:  Clin Exp Nephrol       Date:  2014-10-16       Impact factor: 2.801

4.  Association of serum bicarbonate with incident functional limitation in older adults.

Authors:  Robert Yenchek; Joachim H Ix; Dena E Rifkin; Michael G Shlipak; Mark J Sarnak; Melissa Garcia; Kushang V Patel; Suzanne Satterfield; Tamara B Harris; Anne B Newman; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-07       Impact factor: 8.237

5.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

6.  Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Angelo Karaboyas; Bruce M Robinson; Hal Morgenstern; Jinyao Zhang; Ananda Sen; T Alp Ikizler; Hugh Rayner; Rachel B Fissell; Raymond Vanholder; Tadashi Tomo; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2013-05-24       Impact factor: 8.860

7.  Serum bicarbonate and mortality in adults in NHANES III.

Authors:  Kalani L Raphael; Yingying Zhang; Guo Wei; Tom Greene; Alfred K Cheung; Srinivasan Beddhu
Journal:  Nephrol Dial Transplant       Date:  2013-01-24       Impact factor: 5.992

8.  Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.

Authors:  Csaba P Kovesdy; John E Anderson; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2008-11-17       Impact factor: 5.992

Review 9.  Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy.

Authors:  Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Clin Nutr       Date:  2013-05-01       Impact factor: 7.045

10.  Global gene expression analysis of lenses from different mouse strains and in the alpha3Cx46 knockout mouse.

Authors:  Yajun Tang; Thomas E Crowley; Nalin M Kumar
Journal:  Mol Vis       Date:  2010-01-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.